Tirzepatide 20 mg is the mid-range lyophilised LY3298176 vial — the balanced, general-purpose presentation for routine BuyRetaUK laboratory programmes where a single reconstitution supports multi-well work at a manageable per-milligram cost.
Tirzepatide 20 mg is a 20-milligram lyophilised LY3298176 vial released to ≥99% HPLC-UV with mass-spectrometric identity. It is the mid-range presentation in the BuyRetaUK Tirzepatide catalogue — the default choice for routine, general-purpose laboratory programmes that outgrow the 10 mg pilot format.
Tirzepatide 20 mg is a single lyophilised vial containing 20 milligrams of Tirzepatide (LY3298176), a synthetic dual GLP-1 / GIP receptor agonist. It sits in the middle of the BuyRetaUK stocked strength ladder and is the routine, general-purpose choice for laboratory programmes that outgrow the 10 mg entry vial without yet needing the 40 mg extended presentation.
For pharmacology see Tirzepatide Mechanism of Action; for cornerstone reference material see What is Tirzepatide?.
Step down to the Tirzepatide 10 mg vial for pilot or method-development work; step up to the Tirzepatide 40 mg vial for sustained or higher-throughput programmes. Every stocked strength shares the same release specification — see the Strengths Hub for the full comparison table.
Every vial ships with a batch-specific COA · UK dispatch
The 20 mg vial is released under the same synthesis and analytical framework as every other stocked Tirzepatide strength — see laboratory quality for methodology and acceptance criteria.
Reverse-phase HPLC quantifies purity as a percentage of total peak area. Release specification: ≥99%.
Learn more →Certificate of AnalysisEvery batch ships with a batch-specific COA reporting identity, purity and appearance.
Learn more →Laboratory QualityIndependent third-party analysis, temperature-controlled UK storage and full batch traceability.
Learn more →Batch VerificationCross-reference the batch number printed on your vial against our live COA library.
Learn more →Storage StandardsLyophilised at 2–8°C protected from light. Reconstituted stability ~30 days at 2–8°C.
Learn more →Every 20 mg vial ships with a batch-specific Certificate of Analysis. Cross-check the batch number against the verification library on arrival — the section-by-section walk-through lives in the Certificate of Analysis guide.
The 20 mg vial is released against the same ≥99% HPLC-UV area-percent specification as every stocked strength, with orthogonal identity confirmation by ESI-MS. Method detail lives in Tirzepatide Purity.
Store sealed 20 mg vials at −20 °C for extended holding, or at 2–8 °C for short-term working stock. Once reconstituted with bacteriostatic water, refrigerate the vial at 2–8 °C and consume within four to six weeks — a 20 mg reconstitution particularly benefits from an aliquot strategy set at reconstitution. Full guidance in Tirzepatide Storage & Reconstitution.
A 20 mg reconstitution is worth aliquoting to keep freeze-thaw exposure per aliquot to a single cycle.
Fixing the volume across batches keeps working concentration comparable when a study spans multiple vials.
Order enough 20 mg vials to cover the study without over-committing shelf life.
Cross-reference each vial's batch number against the published Certificate of Analysis.
It carries enough peptide to serve most multi-well or multi-plate in-vitro workflows from a single reconstitution while remaining small enough that reconstituted stock is consumed within a sensible in-use window — the balance point of the stocked ladder.
Reconstituting a 20 mg vial in 2 mL of bacteriostatic water yields 10 mg/mL; in 4 mL yields 5 mg/mL; in 1 mL yields 20 mg/mL. The reconstitution calculator returns the exact diluent volume for any target working concentration.
20 mg is twice the packaged mass at a lower per-milligram cost, so it typically becomes the right choice as soon as a protocol will consume more than one 10 mg vial. Both share the same ≥99% HPLC-UV release specification.
Choose 40 mg for sustained or higher-throughput programmes where per-milligram economics dominate, or where consolidating a workflow onto fewer batches simplifies batch-to-batch reconciliation. For general-purpose routine work, 20 mg is usually the balance point.
No. Every stocked Tirzepatide vial is manufactured under the same synthesis and release framework, with identical HPLC-UV purity and ESI-MS identity confirmation reported on the batch-specific Certificate of Analysis.
Reconstitute once, then split the working stock into single-use aliquots sized to the daily or weekly volume the protocol consumes, frozen once and thawed once. The Tirzepatide storage guide covers freeze-thaw handling in detail.
No. All BuyRetaUK Tirzepatide vials, including the 20 mg vial, are supplied for in-vitro laboratory research only and are not intended for human or veterinary administration.
Peer-reviewed citations are added as each article is expanded. See our editorial standards for our sourcing and accuracy commitments.
The BuyRetaUK editorial team publishes laboratory-focused reference content on research peptides, analytical methods and Certificates of Analysis. All articles are written for in-vitro research contexts only.
View profile →Every editorial article is reviewed against our accuracy commitment and quality-assurance checklist before publication. Named reviewer profiles are added as our reviewer network expands.
View profile →Every article follows a documented editorial process — sourcing, scientific review, update cadence and correction policy — so researchers can rely on what we publish.
Read the full editorial standards →Educational first. Each step is optional — start wherever you are in your research.
Dual GIP/GLP-1 receptor overview and research framing.
How dual receptor engagement drives the incretin response.
Published evidence base, SURPASS & SURMOUNT programmes, laboratory applications.
Phase 3 SURPASS & SURMOUNT read-outs and the peer-reviewed literature.
Dual vs triple incretin agonist — how they differ.
HPLC purity and Certificate of Analysis verification.
Lyophilised storage, bacteriostatic water reconstitution, in-use stability.
Every tirzepatide vial strength available.
UK commercial hub — lab data, COAs and dispatch.
Triple vs dual incretin agonist — receptor profile and research framing.
View comparison →Side by sideSelective GLP-1 agonist vs dual GIP/GLP-1 agonist — receptor pharmacology and evidence comparison.
View comparison →Multi-compoundAll GLP-1 / GIP / glucagon research compounds in one place.
View comparison →How to store lyophilised research peptides and reconstitute them correctly for laboratory use.
4 min read →RetatrutideA laboratory overview of retatrutide (LY3437943) — a triple agonist research peptide acting on the GLP-1, GIP and glucagon receptors.
6 min read →RetatrutideBackground on retatrutide in the academic literature — receptor pharmacology, study context and analytical handling.
8 min read →Product ComparisonsSide-by-side comparison of retatrutide and tirzepatide across receptor profile, research context and analytical considerations.
5 min read →Every batch of Tirzepatide ships with a third-party HPLC and mass-spec Certificate of Analysis. Browse the live COA library to verify your lot.
Long-term frozen storage (-20°C) is acceptable for lyophilised vials, but routine refrigerated storage at 2–8°C is sufficient for typical research timelines.
Read: Storage & Reconstitution →
